EUVIMEDEUVIMED entdecken
Crossref

Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation

Tzu-Ning Tseng, Wen-Juei Jeng iD, Tsung-Hui Hu iD, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Chien-Hung Chen

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkac409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Tzu-Ning Tseng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicin…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Tenofovir. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Ministry of Science and Technology, Chang Gung Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For patients with chronic hepatitis B (CHB), the optimal stopping criteria for entecavir or tenofovir disoproxil fumarate treatment remain unclear.

Methods

This study recruited CHB patients with levels of hepatitis B surface antigen (HBsAg) <100 IU/mL at the end of treatment (EOT) from Kaohsiung (n = 190) and Linkou (n = 188) Chang Gung Memorial Hospitals for use as development and validation groups, respectively.

Results

In the development group, 108 patients with HBsAg ≤40 IU/mL were used for analysis of predictors of HBV relapse and HBsAg loss. Multivariate analysis showed that age, nucleos(t)ide analogue (NA)-experienced status, baseline hepatitis B core-related antigen (HBcrAg) and HBsAg at EOT were associated independently with virological and clinical relapse. An HBsAg level of 20 IU/mL at EOT was the best cut-off value for minimizing HBV relapse. Patients with EOT HBsAg ≤20 IU/mL had lower virological and clinical relapse rates and higher HBsAg loss rates than those with EOT HBsAg 21–40 IU/mL and HBsAg 41–100 IU/mL in the development and validation groups. The virological and clinical relapse rates were very low (5-year rates: 6.5% and 0%, respectively) and HBsAg loss rate was very high (5-year rate: 81.7%) in patients with a combination of baseline HBcrAg ≤4 log U/mL and EOT HBsAg ≤20 IU/mL in the development group.

Conclusions

A combination of baseline HBcrAg ≤4 log U/mL and EOT HBsAg level ≤20 IU/mL might reduce the risk of HBV relapse and increase HBsAg loss rate, and might be helpful for off-NA follow-up strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B Surface AntigensHepatitis B, ChronicTenofovirWithholding TreatmentHumansDNA, ViralHepatitis B e AntigensHepatitis B virusRecurrenceTreatment OutcomeGuanine

Substanzen

Antiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensTenofovirentecavirGuanine

Autor:innen und Institutionen

  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

ORCID-Profile: Wen-Juei Jeng, Tsung-Hui Hu

Förderung

  • Ministry of Science and Technology
  • Chang Gung Memorial Hospital

Zitieren

APA

Tseng, T. N., Jeng, W. J., Hu, T. H., Wang, J. H., Hung, C. H., Lu, S. N., & Chen, C. H. (2023). Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac409

Vancouver

Tseng TN, Jeng WJ, Hu TH, Wang JH, Hung CH, Lu SN, et al. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac409

BibTeX
@article{Tseng2023,
  author = {Tseng, Tzu-Ning and Jeng, Wen-Juei and Hu, Tsung-Hui and Wang, Jing-Houng and Hung, Chao-Hung and Lu, Sheng-Nan and Chen, Chien-Hung},
  title = {Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkac409}
}
Kostenlos starten →